

February 15, 2018

BD Completes Asset Divestitures to Merit Medical

Divestitures Satisfy All Contingencies from Regulatory Authorities Related to Acquisition of C. R. Bard, Inc.

FRANKLIN LAKES, N.J., Feb. 15, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has completed the previously announced divestitures of its soft tissue core needle biopsy product line and Aspira[®] product line to Merit Medical Systems, Inc. following receipt of all required regulatory approvals for such divestitures.



The completion of the divestitures satisfies the remaining contingencies within the previously received regulatory approvals in the U.S., Europe and China for BD's acquisition of C. R. Bard, Inc., which was completed on Dec. 29, 2017.

This sale will not have a material impact on revenue or earnings for fiscal 2018.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.

Contacts:

Troy Kirkpatrick
BD Public Relations
858.617.2361
troy.kirkpatrick@bd.com

Monique N. Dolecki
BD Investor Relations
201.847.5378
Monique_Dolecki@bd.com

 View original content with multimedia: <http://www.prnewswire.com/news-releases/bd-completes-asset-divestitures-to-merit-medical-300598804.html>

SOURCE BD (Becton, Dickinson and Company)